INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the U.S.A. only
Boehringer Ingelheim today announced that the final patient has been randomised to treatment in the large-scale Phase III clinical trial programme for BI 201335, its investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV).
